Low Estrogen After Menopause: Ovarian Aging & Contributing Factors

Menopause (final menstrual period, confirmed after 12 months amenorrhea) marks the end of ovarian follicular activity. Estrogen decline is gradual, beginning years prior (perimenopause).

Primary Mechanisms

1. Follicular Depletion: Fixed ovarian reserve (~1–2 million at birth → ~1000 at menopause). No neooogenesis. Declining inhibin B → loss of negative feedback on FSH.
2. Gonadotropin Rise: FSH ↑↑ (10–20×), LH ↑ (3×). Ovaries become resistant to FSH due to reduced follicle count and altered receptor sensitivity.
3. Enzyme Activity Decline: Aromatase (androgen → estrogen), 17β-HSD, StAR protein expression decrease with ovarian aging.
4. Genetic Modifiers: FMR1 premutation, BRCA1/2, MCM8/9, POLG variants influence age at menopause.

Secondary Contributors

• Smoking → 1–2 yr earlier menopause (toxic to follicles).
• Chemo/radiation → acute ovarian failure.
• Oophorectomy → surgical menopause (abrupt drop).
• Autoimmune oophoritis (associated with adrenal insufficiency, thyroiditis).

Clinical Consequences

• Vasomotor symptoms (hot flashes, night sweats).
• Genitourinary syndrome of menopause (GSM): atrophy, dyspareunia, recurrent UTI.
• Bone: Accelerated resorption → osteoporosis.
• Cardiovascular: Loss of endothelial protection → ↑ CVD risk.
• Cognitive/Mood: Estrogen receptors in hippocampus, amygdala.

Management Options

• MHT (Menopausal Hormone Therapy): Estrogen ± progestin; individualized risk-benefit (WHI data, timing hypothesis).
• Non-hormonal: SSRIs/SNRIs, gabapentin, fezolinetant (NK3 antagonist), vaginal estrogen (low-dose, minimal systemic absorption).
• Lifestyle: Weight-bearing exercise, calcium/vitamin D, smoking cessation, Mediterranean diet.

Estrogen decline is a natural continuum; symptom burden and long-term risks guide personalized therapy.